Literature DB >> 20089531

Alpha-actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle.

Kate G R Quinlan1, Jane T Seto, Nigel Turner, Aurelie Vandebrouck, Matthias Floetenmeyer, Daniel G Macarthur, Joanna M Raftery, Monkol Lek, Nan Yang, Robert G Parton, Gregory J Cooney, Kathryn N North.   

Abstract

Approximately one billion people worldwide are homozygous for a stop codon polymorphism in the ACTN3 gene (R577X) which results in complete deficiency of the fast fibre muscle protein alpha-actinin-3. ACTN3 genotype is associated with human athletic performance and alpha-actinin-3 deficient mice [Actn3 knockout (KO) mice] have a shift in the properties of fast muscle fibres towards slower fibre properties, with increased activity of multiple enzymes in the aerobic metabolic pathway and slower contractile properties. alpha-Actinins have been shown to interact with a number of muscle proteins including the key metabolic regulator glycogen phosphorylase (GPh). In this study, we demonstrated a link between alpha-actinin-3 and glycogen metabolism which may underlie the metabolic changes seen in the KO mouse. Actn3 KO mice have higher muscle glycogen content and a 50% reduction in the activity of GPh. The reduction in enzyme activity is accompanied by altered post-translational modification of GPh, suggesting that alpha-actinin-3 regulates GPh activity by altering its level of phosphorylation. We propose that the changes in glycogen metabolism underlie the downstream metabolic consequences of alpha-actinin-3 deficiency. Finally, as GPh has been shown to regulate calcium handling, we examined calcium handling in KO mouse primary mouse myoblasts and find changes that may explain the slower contractile properties previously observed in these mice. We propose that the alteration in GPh activity in the absence of alpha-actinin-3 is a fundamental mechanistic link in the association between ACTN3 genotype and human performance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089531     DOI: 10.1093/hmg/ddq010

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

1.  The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance.

Authors:  Fleur C Garton; Peter J Houweling; Damjan Vukcevic; Lyra R Meehan; Fiona X Z Lee; Monkol Lek; Kelly N Roeszler; Marshall W Hogarth; Chrystal F Tiong; Diana Zannino; Nan Yang; Stephen Leslie; Paul Gregorevic; Stewart I Head; Jane T Seto; Kathryn N North
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

Review 2.  Rodent models for resolving extremes of exercise and health.

Authors:  Fleur C Garton; Kathryn N North; Lauren G Koch; Steven L Britton; Gisela Nogales-Gadea; Alejandro Lucia
Journal:  Physiol Genomics       Date:  2015-09-22       Impact factor: 3.107

3.  Analysis of the ACTN3 heterozygous genotype suggests that α-actinin-3 controls sarcomeric composition and muscle function in a dose-dependent fashion.

Authors:  Marshall W Hogarth; Fleur C Garton; Peter J Houweling; Taru Tukiainen; Monkol Lek; Daniel G Macarthur; Jane T Seto; Kate G R Quinlan; Nan Yang; Stewart I Head; Kathryn N North
Journal:  Hum Mol Genet       Date:  2015-12-17       Impact factor: 6.150

Review 4.  More than a 'speed gene': ACTN3 R577X genotype, trainability, muscle damage, and the risk for injuries.

Authors:  Juan Del Coso; Danielle Hiam; Peter Houweling; Laura M Pérez; Nir Eynon; Alejandro Lucía
Journal:  Eur J Appl Physiol       Date:  2018-10-16       Impact factor: 3.078

5.  The ACTN3 genotype in soccer players in response to acute eccentric training.

Authors:  Eduardo Mendonça Pimenta; Daniel Barbosa Coelho; Izinara Rosse Cruz; Rodrigo Figueiredo Morandi; Christiano Eduardo Veneroso; Guilherme de Azambuja Pussieldi; Maria Raquel Santos Carvalho; Emerson Silami-Garcia; José Antonio De Paz Fernández
Journal:  Eur J Appl Physiol       Date:  2011-08-13       Impact factor: 3.078

6.  ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling.

Authors:  Jane T Seto; Kate G R Quinlan; Monkol Lek; Xi Fiona Zheng; Fleur Garton; Daniel G MacArthur; Marshall W Hogarth; Peter J Houweling; Paul Gregorevic; Nigel Turner; Gregory J Cooney; Nan Yang; Kathryn N North
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

7.  Transgenic muscle-specific Nor-1 expression regulates multiple pathways that effect adiposity, metabolism, and endurance.

Authors:  Michael A Pearen; Joel M Goode; Rebecca L Fitzsimmons; Natalie A Eriksson; Gethin P Thomas; Gary J Cowin; S-C Mary Wang; Zewen K Tuong; George E O Muscat
Journal:  Mol Endocrinol       Date:  2013-09-24

8.  Update from the 2013 International Neurofibromatosis Conference.

Authors:  Scott R Plotkin; Anne C Albers; Dusica Babovic-Vuksanovic; Jaishri O Blakeley; Xandra O Breakefield; Courtney M Dunn; D Gareth Evans; Michael J Fisher; Jan M Friedman; Marco Giovannini; David H Gutmann; Michel Kalamarides; Andrea I McClatchey; Ludwine Messiaen; Helen Morrison; David B Parkinson; Anat O Stemmer-Rachamimov; Catherine D Van Raamsdonk; Vincent M Riccardi; Tena Rosser; Aaron Schindeler; Miriam J Smith; David A Stevenson; Nicole J Ullrich; Thijs van der Vaart; Brian Weiss; Brigitte C Widemann; Yuan Zhu; Annette C Bakker; Alison C Lloyd
Journal:  Am J Med Genet A       Date:  2014-09-24       Impact factor: 2.802

Review 9.  Mechanisms governing the health and performance benefits of exercise.

Authors:  D Bishop-Bailey
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

10.  ACTN3 genotype, athletic status, and life course physical capability: meta-analysis of the published literature and findings from nine studies.

Authors:  Tamuno Alfred; Yoav Ben-Shlomo; Rachel Cooper; Rebecca Hardy; Cyrus Cooper; Ian J Deary; David Gunnell; Sarah E Harris; Meena Kumari; Richard M Martin; Colin N Moran; Yannis P Pitsiladis; Susan M Ring; Avan Aihie Sayer; George Davey Smith; John M Starr; Diana Kuh; Ian N M Day
Journal:  Hum Mutat       Date:  2011-07-20       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.